These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39043735)

  • 1. Exploring transcriptomic databases: unraveling circadian gene disruptions in lower grade glioma.
    Hou W; Hou W; Zhao X
    Sci Rep; 2024 Jul; 14(1):16960. PubMed ID: 39043735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between deregulated expression of PER2 gene and degree of glioma malignancy.
    Wang F; Luo Y; Li C; Chen L
    Tumori; 2014; 100(6):e266-72. PubMed ID: 25688509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
    Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
    Front Immunol; 2021; 12():668391. PubMed ID: 34539622
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ma W; Zhang K; Bao Z; Jiang T; Zhang Y
    Front Immunol; 2021; 12():659659. PubMed ID: 33936093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-omics landscape of circadian rhythm pathway alterations in Glioma.
    Zhang C; Xu J; Chen L; Lin X
    Bioengineered; 2021 Dec; 12(1):3294-3308. PubMed ID: 34224318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
    Su X; Li H; Chen S; Qin C
    Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma.
    Liu H; Weng J
    Gene; 2022 May; 822():146325. PubMed ID: 35183683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.
    Deng T; Gong YZ; Wang XK; Liao XW; Huang KT; Zhu GZ; Chen HN; Guo FZ; Mo LG; Li LQ
    Med Sci Monit; 2019 May; 25():3716-3727. PubMed ID: 31104065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
    Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
    Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
    Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
    Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The analysis of deregulated expression and methylation of the PER2 genes in gliomas.
    Fan W; Chen X; Li C; ; Chen L; Liu P; Chen Z
    J Cancer Res Ther; 2014; 10(3):636-40. PubMed ID: 25313752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
    Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
    Front Immunol; 2020; 11():606164. PubMed ID: 33408717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
    Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
    Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying hub circadian rhythm biomarkers and immune cell infiltration in rheumatoid arthritis.
    Wen P; Ma T; Zhang B; Hao L; Wang Y; Guo J; Song W; Wang J; Zhang Y
    Front Immunol; 2022; 13():1004883. PubMed ID: 36238290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
    Lin WW; Ou GY; Zhao WJ
    J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.